A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

Publisher： Karger

E-ISSN： 1423-0232|76|5|326-332

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.5, 2009-03, pp. : 326-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 134-142

Karger

Access to resources Recommend Favorite

Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 324-327

Karger

Access to resources Recommend Favorite

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-04 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2612-2617

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2325-2333

John Wiley & Sons Inc

Access to resources Recommend Favorite